Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis.
作者信息
Wallach Joshua D, Egilman Alexander C, Ross Joseph S, Woloshin Steven, Schwartz Lisa M
机构信息
Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, USA.
Collaboration for Research Integrity and Transparency, Yale School of Medicine, New Haven, CT, USA.
出版信息
J Gen Intern Med. 2019 Apr;34(4):492-495. doi: 10.1007/s11606-018-4779-x.
Abstract
摘要
相似文献
1
Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis.
J Gen Intern Med. 2019 Apr;34(4):492-495. doi: 10.1007/s11606-018-4779-x.
2
The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
Clin Trials. 2018 Jun;15(3):219-229. doi: 10.1177/1740774518770648.
3
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
BMJ. 2018 May 24;361:k2031. doi: 10.1136/bmj.k2031.
4
Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
JAMA Netw Open. 2019 May 3;2(5):e193410. doi: 10.1001/jamanetworkopen.2019.3410.
5
Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
JAMA Intern Med. 2014 Jan;174(1):90-5. doi: 10.1001/jamainternmed.2013.11813.
6
Safety in numbers--monitoring risk in approved drugs.
N Engl J Med. 2005 Mar 24;352(12):1173-6. doi: 10.1056/NEJMp058029.
7
US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
Clin Trials. 2021 Aug;18(4):488-499. doi: 10.1177/17407745211005044. Epub 2021 Apr 16.
8
How pharmaceuticals are developed.
J Am Dent Assoc. 1994 Jan;125 Suppl:40S-44S. doi: 10.14219/jada.archive.1994.0259.
9
Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015.
JAMA Netw Open. 2020 Jul 1;3(7):e209498. doi: 10.1001/jamanetworkopen.2020.9498.
10
Publication and Reporting of the Results of Postmarket Studies for Drugs Required by the US Food and Drug Administration, 2009 to 2013.
JAMA Intern Med. 2017 Aug 1;177(8):1207-1210. doi: 10.1001/jamainternmed.2017.1313.
引用本文的文献
1
Accelerating the approval of mpox vaccines based on lessons learnt from COVID-19 vaccines through the lens of regulatory science.
BMJ Glob Health. 2025 Aug 14;10(8):e018517. doi: 10.1136/bmjgh-2024-018517.
2
Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study.
BMJ Med. 2024 Apr 5;3(1):e000802. doi: 10.1136/bmjmed-2023-000802. eCollection 2024.
3
Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics.
JAMA Netw Open. 2023 Aug 1;6(8):e2331753. doi: 10.1001/jamanetworkopen.2023.31753.
4
Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
BMJ Open. 2023 Jun 7;13(6):e069132. doi: 10.1136/bmjopen-2022-069132.
5
Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
JAMA Health Forum. 2022 May 27;3(5):e221158. doi: 10.1001/jamahealthforum.2022.1158. eCollection 2022 May.
6
Post-Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004-2014.
Clin Pharmacol Ther. 2022 Oct;112(4):846-852. doi: 10.1002/cpt.2679. Epub 2022 Jun 23.
7
Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.
JAMA Netw Open. 2022 May 2;5(5):e2212454. doi: 10.1001/jamanetworkopen.2022.12454.
8
New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence.
Drug Saf. 2022 Apr;45(4):305-318. doi: 10.1007/s40264-022-01152-9. Epub 2022 Feb 19.
9
Experts' Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care.
J Gen Intern Med. 2022 Dec;37(16):4176-4182. doi: 10.1007/s11606-021-07316-0. Epub 2022 Feb 9.
10
Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018.
JAMA Netw Open. 2021 Nov 1;4(11):e2133601. doi: 10.1001/jamanetworkopen.2021.33601.
本文引用的文献
1
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
BMJ. 2018 May 24;361:k2031. doi: 10.1136/bmj.k2031.
2
The Fate of FDA Postapproval Studies.
N Engl J Med. 2017 Sep 21;377(12):1114-1117. doi: 10.1056/NEJMp1705800.
3
Publication and Reporting of the Results of Postmarket Studies for Drugs Required by the US Food and Drug Administration, 2009 to 2013.
JAMA Intern Med. 2017 Aug 1;177(8):1207-1210. doi: 10.1001/jamainternmed.2017.1313.
4
A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
JAMA. 2012 Jun 20;307(23):2491-2. doi: 10.1001/jama.2012.5545.
Zotero 插件